glp 1 agonist alternative How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments i wanted to hate this

Description

Chronic Disease Prevalence : Rising global rates of type 2 diabetes and obesity are expanding the patient pool for GLP1 therapies, increasing demand for both glycemic and weight management indications

doi: 10.1007/s42000-018-0038-0 [DOI] [PubMed] [Google Scholar] 125

Surprisingly, a slight improvement in change of peak oxygen consumption (peak VO 2 ) was observed in the albiglutide group compared with placebo (mean 0.9 0.5 ml/kg/min versus 0.6 0.5 ml/kg/min

Diabetes Care 34(Supplement_2):S279-84 Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Articles were reviewed for efficacy at reducing A1c (Tables 1 and 2) or for other clinical effects including effect on weight, blood pressure (BP), or other drug-related outcomes